ACTU Actuate Therapeutics, Inc.
-
Actuate Therapeutics Beat Consensus Estimates
Friday, August 14, 2026 · 12:00 AM ET
Actuate Therapeutics (ACTU) reported a loss of $0.20 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus estimate was a loss of $0.21 per share. The company beat consensus estimates by 4.76%.
Actuate Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers. The company's lead product includes elraglusib. Actuate Therapeutics Inc. is based in FORT WORTH, Texas.
Reported Earnings
($0.20)
Earnings Whisper®
—
Consensus Estimate
($0.21)
Earnings Surprise
Earnings Growth
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth—